|
1
|
Zhang H, Zhong X, Zhang X, Shang D, Zhou
YI and Zhang C: Enhanced anticancer effect of ABT-737 in
combination with naringenin on gastric cancer cells. Exp Ther Med.
11:669–673. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hamashima C: The burden of gastric cancer.
Ann Transl Med. 8:7342020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng
G, Guo M, Lian X, Fan D and Zhang H: Diagnostic and prognostic
value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC
Cancer. 17:7372017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thanh Huong P, Gurshaney S, Thanh Binh N,
Gia Pham A, Hoang Nguyen H, Thanh Nguyen X, Pham-The H, Tran PT,
Truong Vu K, Xuan Duong N, et al: Emerging role of circulating
tumor cells in gastric cancer. Cancers (Basel). 12:6952020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hussain SP and Harris CC: Inflammation and
cancer: An ancient link with novel potentials. Int J Cancer.
121:2373–2380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen L, Hao Y, Zhu L, Li S, Zuo Y, Zhang
Y, Song H and Xue Y: Monocyte to lymphocyte ratio predicts survival
in patients with advanced gastric cancer undergoing neoadjuvant
chemotherapy. Onco Targets Ther. 10:4007–4016. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Y, Xu H, Jiang H, Ding S and Zheng
T: Pretreatment neutrophil-lymphocyte count ratio may associate
with gastric cancer presence. Cancer Biomark. 16:523–528. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pietrzyk L, Plewa Z, Denisow-Pietrzyk M,
Zebrowski R and Torres K: Diagnostic power of blood parameters as
screening markers in gastric cancer patients. Asian Pac J Cancer
Prev. 17:4433–4437. 2016.PubMed/NCBI
|
|
9
|
Beyazit Y, Kekilli M, Ibis M, Kurt M,
Sayilir A, Onal IK, Purnak T, Oztas E, Tas A, Yesil Y and Arhan M:
Can red cell distribution width help to discriminate benign from
malignant biliary obstruction? A retrospective single center
analysis. Hepatogastroenterology. 59:1469–1473. 2012.PubMed/NCBI
|
|
10
|
Spell DW, Jones DV Jr, Harper WF and David
Bessman J: The value of a complete blood count in predicting cancer
of the colon. Cancer Detect Prev. 28:37–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhahbi JM, Atamna H, Li R, Yamakawa A,
Guerrero N, Lam HT, Mote P and Spindler SR: MicroRNAs circulate in
the hemolymph of drosophila and accumulate relative to tissue
microRNAs in an Age-dependent manner. Genomics Insights. 9:29–39.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schetter AJ, Heegaard NH and Harris CC:
Inflammation and cancer: Interweaving microRNA, free radical,
cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garrido-Cano I, Constâncio V,
Adam-Artigues A, Lameirinhas A, Simón S, Ortega B, Martínez MT,
Hernando C, Bermejo B, Lluch A, et al: Circulating miR-99a-5p
expression in plasma: A potential biomarker for early diagnosis of
breast cancer. Int J Mol Sci. 21:74272020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghosh S, Bhowmik S, Majumdar S, Goswami A,
Chakraborty J, Gupta S, Aggarwal S, Ray S, Chatterjee R,
Bhattacharyya S, et al: The exosome encapsulated microRNAs as
circulating diagnostic marker for hepatocellular carcinoma with low
alpha fetoprotein. Int J Cancer. 147:2934–2947. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ying L, Du L, Zou R, Shi L, Zhang N, Jin
J, Xu C, Zhang F, Zhu C, Wu J, et al: Development of a serum miRNA
panel for detection of early stage non-small cell lung cancer. Proc
Natl Acad Sci USA. 117:25036–25042. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X and Chu KM: Exosomal miRNAs as
circulating biomarkers for prediction of development of
haematogenous metastasis after surgery for stage II/III gastric
cancer. J Cell Mol Med. 24:6220–6232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong Y, Ning L, Qiu F, Yu Q and Cao B:
Clinical significance of serum miR-25 as a diagnostic and
prognostic biomarker in human gastric cancer. Cancer Biomark.
24:477–483. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Wu L, Sun Y, Luo C, Chen X, Wu L,
Ding J, Pan G, Han C, Wu Z and Shen Y: Diagnostic value and
clinical significance of circulating miR-650 and CA211 in detecting
of gastric carcinoma. Oncol Lett. 20:2542020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Catalano V, Sisti V, Spada D, Graziano F,
Cicetti M, Alessandroni PGP, Baldelli AM, Casadei V, Fedeli SL,
Rossi D, et al: Assessment of the 7th edition of the AJCC
classification and a proposal of a new classification in patients
with gastric cancer undergoing D2 gastrectomy. J Clin Oncol. 30
(Suppl 15):S40842012. View Article : Google Scholar
|
|
20
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO Classification of Tumours of the Digestive System.
World Health Organization Classification of Tumours. 3. 4th
edition. Lyon France: 2010
|
|
21
|
Yamano T, Kubo S, Sonoda E, Kominato T,
Kimura K, Yasuhara M, Kataoka K, Son J, Babaya A, Takenaka Y, et
al: Assessment of circulating microRNA specific for patients with
familial adenomatous polyposis. PLoS One. 16:e02500722021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Wu L, Sun Y, Yin Q, Chen X, Liang
S, Meng Q, Long H, Li F, Luo C and Xiao X: Mir-421 in plasma as a
potential diagnostic biomarker for precancerous gastric lesions and
early gastric cancer. PeerJ. 7:e70022019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burmistrova OA, Goltsov AY, Abramova LI,
Kaleda VG, Orlova VA and Rogaev EI: MicroRNA in schizophrenia:
Genetic and expression analysis of miR-130b (22q11). Biochemistry
(Mosc). 72:578–582. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim Y, Kim H, Bang S, Jee S and Jang K:
MicroRNA-130b functions as an oncogene and is a predictive marker
of poor prognosis in lung adenocarcinoma. Lab Invest. 101:155–164.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ou C, Peng NF, Li H, Peng YC and Li LJQ:
The potential mechanism of miR-130b on promotion of the invasion
and metastasis of hepatocellular carcinoma by inhibiting
Notch-Dll1. J Recept Signal Transduct Res. 40:157–165. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hashimoto Y, Shiina M, Dasgupta P,
Kulkarni P, Kato T, Wong RK, Tanaka Y, Shahryari V, Maekawa S,
Yamamura S, et al: Upregulation of miR-130b contributes to risk of
poor prognosis and racial disparity in African-American prostate
cancer. Cancer Prev Res (Phila). 12:585–598. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Y, Ma Y, Peng H, Gong L, Xiao M, Xiang
L, He D and Cao K: miR-130b promotes the progression of oesophageal
squamous cell carcinoma by targeting SASH1. J Cell Mol Med.
23:93–103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lai KW, Koh KX, Loh M, Tada K, Subramaniam
MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et
al: MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric
cancer. Eur J Cancer. 46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L
and Wang Z: Epigenetic silencing of miR-130b in ovarian cancer
promotes the development of multidrug resistance by targeting
colony-stimulating factor 1. Gynecol Oncol. 124:325–334. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou
H and Jia L: MicroRNA-130b targets PTEN to mediate drug resistance
and proliferation of breast cancer cells via the PI3K/Akt signaling
pathway. Sci Rep. 7:419422017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Q, Zhang B, Sun L, Yan Q, Zhang Y,
Zhang Z, Su Y and Wang C: MicroRNA-130b targets PTEN to induce
resistance to cisplatin in lung cancer cells by activating
Wnt/β-catenin pathway. Cell Biochem Funct. 36:194–202. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colangelo T, Fucci A, Votino C, Sabatino
L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente
D, et al: MicroRNA-130b promotes tumor development and is
associated with poor prognosis in colorectal cancer. Neoplasia.
15:1086–1099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao L, Mao ZG, Jiang H, Qin L, Huang CY
and Tan B: Value of MCV/RDW combined with reticulocyte parameters
in differential diagnosis of Anemia diseases. Zhongguo Shi Yan Xue
Ye Xue Za Zhi. 23:1662–1666. 2015.(In Chinese). PubMed/NCBI
|
|
35
|
Seretis C, Seretis F, Lagoudianakis E,
Gemenetzis G and Salemis NS: Is red cell distribution width a novel
biomarker of breast cancer activity? Data from a pilot study. J
Clin Med Res. 5:121–126. 2013.PubMed/NCBI
|
|
36
|
Sategna Guidetti C, Scaglione N and
Martini S: Red cell distribution width as a marker of coeliac
disease: A prospective study. Eur J Gastroenterol Hepatol.
14:177–181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lippi G, Targher G, Montagnana M, Salvagno
GL, Zoppini G and Guidi GC: Relation between red blood cell
distribution width and inflammatory biomarkers in a large cohort of
unselected outpatients. Arch Pathol Lab Med. 133:628–632. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Y, Xing C, Wei M, Wu H, Hu X, Li S, Sun
G, Zhang G, Wu B, Zhang F and Li Z: Combining red blood cell
distribution width (RDW-CV) and CEA predict poor prognosis for
survival outcomes in colorectal cancer. J Cancer. 10:1162–1170.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qin YY, Wu YY, Xian XY, Qin JQ, Lai ZF,
Liao L and Lin FQ: Single and combined use of red cell distribution
width, mean platelet volume, and cancer antigen 125 for
differential diagnosis of ovarian cancer and benign ovarian tumors.
J Ovarian Res. 11:102018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gilreath JA and Rodgers GM: How I treat
cancer-associated anemia. Blood. 136:801–813. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang X, Zhang F, Qiao W, Zhang X, Zhao Z
and Li M: Low hematocrit is a strong predictor of poor prognosis in
lung cancer patients. Biomed Res Int. 2018:68049382018.PubMed/NCBI
|
|
42
|
Seda CJ, Salas AS, Sánchez CG, Blasco JM,
García IO, Sánchez JM, Ruíz CB, Navarro SM and López RA:
Thrombocytosis and hematocrit as prognostic factors in renal
carcinoma. Arch Esp Urol. 64:883–890. 2011.PubMed/NCBI
|
|
43
|
Chen B, Dai D, Tang H, Ai X, Chen X, Zhang
X, Li Z and Xie X: Pretreatment hematocrit is superior to
hemoglobin as a prognostic factor for triple negative breast
cancer. PLoS One. 11:e01651332016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang S, Lu M, Li Y, Li J and Shen LJCo: A
lower haemoglobin level predicts a worse survival of patients with
advanced gastric cancer. Clin Oncol (R Coll Radiol). 26:239–240.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen J, Li Y and Cui H: Preoperative low
hematocrit is an adverse prognostic biomarker in ovarian cancer.
Arch Gynecol Obstet. 303:767–775. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu F, Hu HJ, Regmi P, Jin YW, Ma WJ, Wang
JK, Zou RQ and Li FY: Elevated platelet distribution width predicts
poor prognosis in gallbladder carcinoma. Cancer Manag Res.
13:4647–4655. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aksoy EK, Kantarcı S, Torgutalp M, Akpınar
MY, Sapmaz FP, Yalçın GŞ, Uzman M, Şimşek GG and Nazlıgül Y: The
importance of complete blood count parameters in the screening of
gastric cancer. Prz Gastroenterol. 14:183–187. 2019.PubMed/NCBI
|
|
48
|
Yun ZY, Li N, Zhang X, Zhang H, Bu Y, Sun
Y, Liu T, Wang RT and Yu KJ: Mean platelet volume, platelet
distribution width and carcinoembryonic antigen to discriminate
gastric cancer from gastric ulcer. Oncotarget. 8:62600–62605. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kılınçalp S, Ekiz F, Başar O, Ayte MR,
Coban S, Yılmaz B, Altınbaş A, Başar N, Aktaş B, Tuna Y and Erbiş
H: Mean platelet volume could be possible biomarker in early
diagnosis and monitoring of gastric cancer. Platelets. 25:592–594.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tuncel T, Ozgun A, Emirzeoglu L, Celik S,
Bilgi O and Karagoz B: Mean platelet volume as a prognostic marker
in metastatic colorectal cancer patients treated with
bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev.
15:6421–6423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun YC, Yang JJ, Suh JT, Lee WI, Lee HJ
and Park TS: Mean platelet volume/platelet count ratio in anemia.
Platelets. 24:244–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Inagaki N, Kibata K, Tamaki T, Shimizu T
and Nomura S: Prognostic impact of the mean platelet
volume/platelet count ratio in terms of survival in advanced
non-small cell lung cancer. Lung Cancer. 83:97–101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Song S, Li C, Li S, Gao H, Lan X and Xue
Y: Derived neutrophil to lymphocyte ratio and monocyte to
lymphocyte ratio may be better biomarkers for predicting overall
survival of patients with advanced gastric cancer. Onco Targets
Ther. 10:3145–3154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Aldemir MN, Turkeli M, Simsek M, Yildirim
N, Bilen Y, Yetimoglu H, Bilici M and Tekin SB: Prognostic value of
baseline neutrophil-lymphocyte and platelet-lymphocyte ratios in
local and advanced gastric cancer patients. Asian Pac J Cancer
Prev. 16:5933–5937. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yu L, Lv CY, Yuan AH, Chen W and Wu AW:
Significance of the preoperative neutrophil-to-lymphocyte ratio in
the prognosis of patients with gastric cancer. World J
Gastroenterol. 21:6280–6286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lian L, Xia YY, Zhou C, Shen XM, Li XL,
Han SG, Zheng Y, Mao ZQ, Gong FR, Wu MY, et al: Application of
platelet/lymphocyte and neutrophil/lymphocyte ratios in early
diagnosis and prognostic prediction in patients with resectable
gastric cancer. Cancer Biomark. 15:899–907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hsu JT, Liao CK, Le PH, Chen TH, Lin CJ,
Chen JS, Chiang KC and Yeh TS: Prognostic value of the preoperative
neutrophil to lymphocyte ratio in resectable gastric cancer.
Medicine (Baltimore). 94:e15892015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Deng Q, He B, Liu X, Yue J, Ying H, Pan Y,
Sun H, Chen J, Wang F, Gao T, et al: Prognostic value of
pre-operative inflammatory response biomarkers in gastric cancer
patients and the construction of a predictive model. J Transl Med.
13:662015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang SH, Wang XL, Cai J and Wang SH:
Diagnostic value of circulating PIGF in combination with Flt-1 in
early cervical cancer. Curr Med Sci. 40:973–978. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Leandersson P, Åkesson A, Hedenfalk I,
Malander S and Borgfeldt C: A multiplex biomarker assay improves
the diagnostic performance of HE4 and CA125 in ovarian tumor
patients. PLoS One. 15:e02404182020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Huang J, Zheng Y, Xiao X, Liu C, Lin J,
Zheng S, Yang B and Ou Q: A circulating long noncoding RNA panel
serves as a diagnostic marker for hepatocellular carcinoma. Dis
Markers. 2020:54175982020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cheng J, Yang A, Cheng S, Feng L, Wu X, Lu
X, Zu M, Cui J, Yu H and Zou L: Circulating miR-19a-3p and
miR-483-5p as novel diagnostic biomarkers for the early diagnosis
of gastric cancer. Med Sci Monit. 26:e9234442020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sun L, Tu H, Chen T, Yuan Q, Liu J, Dong N
and Yuan Y: Three-dimensional combined biomarkers assay could
improve diagnostic accuracy for gastric cancer. Sci Rep.
7:116212017. View Article : Google Scholar : PubMed/NCBI
|
